Matthias Alder
Chief Executive Officer at Gain Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Gain Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Gain Therapeutics Inc. June 24, 202469.2%
-
Gain Therapeutics Inc. June 23, 202399.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2024 | Gain Therapeutics Inc. | Option exercise | +18,750 | — | — |
| Mar 26, 2024 | Gain Therapeutics Inc. | Option exercise | +825 | — | — |
| Mar 26, 2024 | Gain Therapeutics Inc. | Option exercise | +637 | — | — |
| Mar 26, 2024 | Gain Therapeutics Inc. | Shares withheld for tax | −6,085 | $4.06 | $24,705 |
| Dec 21, 2023 | Gain Therapeutics Inc. | Open-market sale | −206 | $2.46 | $507 |
| Dec 20, 2023 | Gain Therapeutics Inc. | Option exercise | +637 | — | — |
| Dec 7, 2023 | Gain Therapeutics Inc. | Open-market sale | −1,820 | $2.50 | $4,550 |
| Oct 1, 2023 | Gain Therapeutics Inc. | Option exercise | +825 | — | — |
| Sep 20, 2023 | Gain Therapeutics Inc. | Option exercise | +2,550 | — | — |
| Jul 1, 2023 | Gain Therapeutics Inc. | Option exercise | +3,300 | — | — |
Questions about Matthias Alder
What boards is Matthias Alder on?
Matthias Alder sits on the board of Gain Therapeutics Inc.
What company is Matthias Alder the CEO of?
Matthias Alder is Chief Executive Officer of Gain Therapeutics Inc.
How long has Matthias Alder served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.